Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

520 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Elexacaftor/tezacaftor/ivacaftor in children aged 6-11 years with cystic fibrosis, at least one F508DEL allele, and advanced lung disease: A 24-week observational study.
Salvatore D, Cimino G, Troiani P, Bignamini E, Esposito I, Leonetti G, Zanda M, Manunza D, Pepe A. Salvatore D, et al. Among authors: esposito i. Pediatr Pulmonol. 2022 Sep;57(9):2253-2256. doi: 10.1002/ppul.25980. Epub 2022 May 25. Pediatr Pulmonol. 2022. PMID: 35577767 No abstract available.
Do not forget asthma comorbidities in pediatric severe asthma!
Ronco L, Folino A, Goia M, Crida B, Esposito I, Bignamini E. Ronco L, et al. Among authors: esposito i. Front Pediatr. 2022 Jul 29;10:932366. doi: 10.3389/fped.2022.932366. eCollection 2022. Front Pediatr. 2022. PMID: 35967579 Free PMC article. Review.
[Italian Cystic Fibrosis Registry (ICFR). Report 2021-2022].
Campagna G, Amato A, Majo F, Ferrari G, Quattrucci S, Padoan R, Floridia G, Salvatore D, Carnovale V, Puppo Fornaro G, Taruscio D, Salvatore M; Gruppo di lavoro RIFC. Campagna G, et al. Epidemiol Prev. 2024 Mar-Apr;48(2 Suppl 2):1-41. doi: 10.19191/EP24.2.S2.031. Epidemiol Prev. 2024. PMID: 38742380 Free article. Italian.
Reported Adverse Events in a Multicenter Cohort of Patients Ages 6-18 Years with Cystic Fibrosis and at Least One F508del Allele Receiving Elexacaftor/Tezacaftor/Ivacaftor.
Terlizzi V, Fevola C, Presti S, Castaldo A, Daccò V, Claut L, Sepe A, Majo F, Casciaro R, Esposito I, Vitullo P, Salvi M, Troiani P, Ficili F, Parisi GF, Pantano S, Costa S, Leonetti G, Palladino N, Taccetti G, Bonomi P, Salvatore D. Terlizzi V, et al. Among authors: esposito i. J Pediatr. 2024 Nov;274:114176. doi: 10.1016/j.jpeds.2024.114176. Epub 2024 Jun 28. J Pediatr. 2024. PMID: 38945446
Corrigendum to "Reported Adverse Events in a Multicenter Cohort of Patients Ages 6-18 years with Cystic Fibrosis and at Least one F508dek Allele Receiving Elexacaftor/Tezacaftor/Ivacaftor". J Pediatr. 2024 Jun 28; 274:114176.
Terlizzi V, Fevola C, Presti S, Castaldo A, Daccò V, Claut L, Sepe A, Majo F, Casciaro R, Esposito I, Vitullo P, Salvi M, Troiani P, Ficili F, Parisi GF, Pantano S, Costa S, Leonetti G, Palladino N, Taccetti G, Bonomi P, Salvatore D. Terlizzi V, et al. Among authors: esposito i. J Pediatr. 2024 Nov;274:114228. doi: 10.1016/j.jpeds.2024.114228. Epub 2024 Aug 28. J Pediatr. 2024. PMID: 39198099 Free article. No abstract available.
520 results